|Other names||Asymmetric septal hypertrophy,|
idiopathic hypertrophic subaortic stenosis
|Symptoms||Feeling tired, leg swelling, shortness of breath, chest pain, fainting|
|Complications||Heart failure, irregular heartbeat, sudden cardiac death|
|Causes||Genetics, Fabry disease, Friedreich's ataxia, certain medications|
|Diagnostic method||Electrocardiogram, echocardiogram, stress testing, genetic testing|
|Differential diagnosis||Hypertensive heart disease, aortic stenosis, athlete's heart|
|Treatment||Medications, implantable cardiac defibrillator, surgery|
|Medication||Beta blockers, diuretics, disopyramide|
|Prognosis||Less than 1% per year risk of death (with treatment)|
|Frequency||1 in 500 people|
Hypertrophic cardiomyopathy (HCM) is a condition in which a portion of the heart becomes thickened without an obvious cause. This results in the heart being less able to pump blood effectively. Symptoms vary from none to feeling tired, leg swelling, and shortness of breath. It may also result in chest pain or fainting. Complications include heart failure, an irregular heartbeat, and sudden cardiac death.
HCM is most commonly inherited from a person's parents. It is often due to mutations in certain genes involved with making heart muscle proteins. Other causes may include Fabry disease, Friedreich's ataxia, and certain medications such as tacrolimus. It is a type of cardiomyopathy, a group of diseases that primarily affects the heart muscle. Diagnosis often involves an electrocardiogram, echocardiogram, and stress testing. Genetic testing may also be done.
Treatment may include the use of beta blockers, diuretics, or disopyramide. An implantable cardiac defibrillator may be recommended in those with certain types of irregular heartbeat. Surgery, in the form of a septal myectomy or heart transplant, may be done in those who do not improve with other measures. With treatment, the risk of death from the disease is less than one percent per year.
HCM affects about one in 500 people. Rates in men and women are about equal. People of all ages may be affected. The first modern description of the disease was by Donald Teare in 1958.
- 1 Signs and symptoms
- 2 Genetics
- 3 Diagnosis
- 4 Screening
- 5 Treatment
- 6 Prognosis
- 7 Children
- 8 Other animals
- 9 References
- 10 External links
Signs and symptoms
The clinical course of HCM is variable. Many people with HCM are asymptomatic or mildly symptomatic, and many of those carrying disease genes for HCM do not have clinically detectable disease. The symptoms and signs of HCM include shortness of breath due to stiffening and decreased blood filling of the ventricles, exertional chest pain (sometimes known as angina) due to reduced blood flow to the coronary arteries, uncomfortable awareness of the heart beat (palpitations), as well as disruption of the electrical system running through the abnormal heart muscle, lightheadedness, weakness, fainting and sudden cardiac death.
Dyspnea is largely due to increased stiffness of the left ventricle (LV), which impairs filling of the ventricles, but also leads to elevated pressure in the left ventricle and left atrium, causing back pressure and interstitial congestion in the lungs. Symptoms are not closely related to the presence or severity of an outflow tract gradient. Often, symptoms mimic those of congestive heart failure (esp. activity intolerance and dyspnea), but treatment of each is different. Beta blockers are used in both cases, but treatment with diuretics, a mainstay of CHF treatment, will exacerbate symptoms in hypertrophic obstructive cardiomyopathy by decreasing ventricular preload volume and thereby increasing outflow resistance (less blood to push aside the thickened obstructing tissue).
Major risk factors for sudden death in individuals with HCM include prior history of cardiac arrest or ventricular fibrillation, spontaneous sustained ventricular tachycardia, family history of premature sudden death, unexplained syncope, LV thickness greater than or equal to 30 mm, abnormal exercise blood pressure and nonsustained ventricular tachycardia.
Currently, about 50–60% of people with a high index of clinical suspicion for HCM will have a mutation identified in at least one of nine sarcomeric genes. Approximately 40% of these mutations occur in the β-myosin heavy chain gene on chromosome 14 q11.2-3, and approximately 40% involve the cardiac myosin-binding protein C gene. Since HCM is typically an autosomal dominant trait, children of a single HCM parent have 50% chance of inheriting the disease-causing mutation. Whenever such a mutation is identified, family-specific genetic testing can be used to identify relatives at-risk for the disease, although clinical severity and age of onset cannot be predicted.
In individuals without a family history of HCM, the most common cause of the disease is a de novo mutation of the gene that produces the β-myosin heavy chain.
An insertion/deletion polymorphism in the gene encoding for angiotensin converting enzyme (ACE) alters the clinical phenotype of the disease. The D/D (deletion/deletion) genotype of ACE is associated with more marked hypertrophy of the left ventricle and may be associated with higher risk of adverse outcomes.
Some mutations could have more harmful potential compared to others (β-myosin heavy chain). For example, troponin T mutations were originally associated with a 50% mortality before the age of 40. However, a more recent and larger study found a similar risk to other sarcomeric protein mutations. The age at disease onset of HCM with MYH7 is earlier and leads to a more severe symptoms.
A diagnosis of hypertrophic cardiomyopathy is based upon a number of features of the disease process. While there is use of echocardiography, cardiac catheterization, or cardiac MRI in the diagnosis of the disease, other important considerations include ECG, genetic testing (although not primarily used for diagnosis), and any family history of HCM or unexplained sudden death in otherwise healthy individuals.
Obstructive or non-obstructive
Depending on whether the distortion of normal heart anatomy causes an obstruction of the outflow of blood from the left ventricle of the heart, HCM can be classified as obstructive or non-obstructive.
- The obstructive variant of HCM, hypertrophic obstructive cardiomyopathy (HOCM), has also historically been known as idiopathic hypertrophic subaortic stenosis (IHSS) and asymmetric septal hypertrophy (ASH).
- Another, non-obstructive variant of HCM is apical hypertrophic cardiomyopathy, also called Yamaguchi Syndrome or Yamaguchi Hypertrophy, first described in individuals of Japanese descent.
Upon cardiac catheterization, catheters can be placed in the left ventricle and the ascending aorta, to measure the pressure difference between these structures. In normal individuals, during ventricular systole, the pressure in the ascending aorta and the left ventricle will equalize, and the aortic valve is open. In individuals with aortic stenosis or with HCM with an outflow tract gradient, there will be a pressure gradient (difference) between the left ventricle and the aorta, with the left ventricular pressure higher than the aortic pressure. This gradient represents the degree of obstruction that has to be overcome in order to eject blood from the left ventricle.
The Brockenbrough–Braunwald–Morrow sign is observed in individuals with HCM with outflow tract gradient. This sign can be used to differentiate HCM from aortic stenosis. In individuals with aortic stenosis, after a premature ventricular contraction (PVC), the following ventricular contraction will be more forceful, and the pressure generated in the left ventricle will be higher. Because of the fixed obstruction that the stenotic aortic valve represents, the post-PVC ascending aortic pressure will increase as well. In individuals with HCM, however, the degree of obstruction will increase more than the force of contraction will increase in the post-PVC beat. The result of this is that the left ventricular pressure increases and the ascending aortic pressure decreases, with an increase in the LVOT gradient.
While the Brockenbrough–Braunwald–Morrow sign is most dramatically demonstrated using simultaneous intra-cardiac and intra-aortic catheters, it can be seen on routine physical examination as a decrease in the pulse pressure in the post-PVC beat in individuals with HCM.
Although HCM may be asymptomatic, affected individuals may present with symptoms ranging from mild to critical heart failure and sudden cardiac death at any point from early childhood to seniority. HCM is the leading cause of sudden cardiac death in young athletes in the United States, and the most common genetic cardiovascular disorder. One study found that the incidence of sudden cardiac death in young competitive athletes declined in the Veneto region of Italy by 89% since the 1982 introduction of routine cardiac screening for athletes, from an unusually high starting rate. As of 2010, however, studies have shown that the incidence of sudden cardiac death, among all people with HCM, has declined to one percent or less. Screen-positive individuals who are diagnosed with cardiac disease are usually told to avoid competitive athletics.
HCM can be detected with an echocardiogram (ECHO) with 80%+ accuracy, which can be preceded by screening with an electrocardiogram (ECG) to test for heart abnormalities. Cardiac magnetic resonance imaging (CMR), considered the gold standard for determining the physical properties of the left ventricular wall, can serve as an alternative screening tool when an echocardiogram provides inconclusive results. For example, the identification of segmental lateral ventricular hypertrophy cannot be accomplished with echocardiography alone. Also, left ventricular hypertrophy may be absent in children under thirteen years of age. This undermines the results of pre-adolescents’ echocardiograms. Researchers, however, have studied asymptomatic carriers of an HCM-causing mutation through the use of CMR and have been able to identify crypts in the interventricular septal tissue in these people. It has been proposed that the formation of these crypts is an indication of myocyte disarray and altered vessel walls that may later result in the clinical expression of HCM. A possible explanation for this is that the typical gathering of family history only focuses on whether sudden death occurred or not. It fails to acknowledge the age at which relatives suffered sudden cardiac death, as well as the frequency of the cardiac events. Furthermore, given the several factors necessary to be considered at risk for sudden cardiac death, while most of the factors do not have strong predictive value individually, there exists ambiguity regarding when to implement special treatment.
There are several potential challenges associated with routine screening for HCM in the United States. First, the U.S. athlete population of 15 million is almost twice as large as Italy's estimated athlete population. Second, these events are rare, with fewer than 100 deaths in the U.S. due to HCM in competitive athletes per year, or about 1 death per 220,000 athletes. Lastly, genetic testing would provide a definitive diagnosis; however, due to the numerous HCM-causing mutations, this method of screening is complex and is not cost-effective. Therefore, genetic testing in the United States is limited to individuals who exhibit clear symptoms of HCM, and their family members. This ensures that the test is not wasted on detecting other causes of ventricular hypertrophy (due to its low sensitivity), and that family members of the individual are educated on the potential risk of being carriers of the mutant gene(s).
Canadian genetic testing guidelines and recommendations for individuals diagnosed with HCM are as follows:
- The main purpose of genetic testing is for screening family members.
- According to the results, at-risk relatives may be encouraged to undergo extensive testing.
- Genetic testing is not meant for confirming a diagnosis.
- If the diagnosed individual has no relatives that are at risk, then genetic testing is not required.
- Genetic testing is not intended for risk assessment or treatment decisions.
- Evidence only supports clinical testing in predicting the progression and risk of developing complications of HCM.
For individuals suspected of having HCM:
- Genetic testing is not recommended for determining other causes of left ventricular hypertrophy (such as "athlete's heart", hypertension, and cardiac amyloidosis).
- HCM may be differentiated from other hypertrophy-causing conditions using clinical history and clinical testing.
A post-mortem following the death of popular TV presenter David Frost in 2013 showed he suffered from HCM, though it didn’t contribute to his death and his family wasn’t informed. The sudden cardiac death of his 31-year-old son in 2015 led the family to collaborate with the British Heart Foundation to raise funds for better screening.
A significant number of people with hypertrophic cardiomyopathy do not have any symptoms and will have normal life expectancies, although they should avoid particularly strenuous activities or competitive athletics, and should be screened for risk factors for sudden cardiac death. In people with resting or inducible outflow obstructions, situations that will cause dehydration or vasodilation (such as the use of vasodilatory or diuretic blood pressure medications) should be avoided. Septal reduction therapy is not recommended in asymptomatic people.
The primary goal of medications is to relieve symptoms such as chest pain, shortness of breath, and palpitations. Beta blockers are considered first-line agents, as they can slow down the heart rate and decrease the likelihood of ectopic beats. For people who cannot tolerate beta blockers, nondihydropyridine calcium channel blockers such as verapamil can be used, but are potentially harmful in people who also have low blood pressure or severe shortness of breath at rest. These medications also decrease the heart rate, though their use in people with severe outflow obstruction, elevated pulmonary artery wedge pressure, and low blood pressures should be done with caution. Dihydropyridine calcium channel blockers should be avoided in people with evidence of obstruction. For people whose symptoms are not relieved by the above treatments, disopyramide can be considered for further symptom relief. Diuretics can be considered for people with evidence of fluid overload, though cautiously used in those with evidence of obstruction. People who continue to have symptoms despite drug therapy can consider more invasive therapies. Intravenous phenylephrine (or another pure vasoconstricting agent) can be used in the acute setting of low blood pressure in those with obstructive hypertrophic cardiomyopathy who do not respond to fluid administration.
Surgical septal myectomy
Surgical septal myectomy is an open-heart operation done to relieve symptoms in people who remain severely symptomatic despite medical therapy. It has been performed successfully since the early 1960s. Surgical septal myectomy uniformly decreases left ventricular outflow tract obstruction and improves symptoms, and in experienced centers has a surgical mortality of less than 1%, as well as 85% success rate. It involves a median sternotomy (general anesthesia, opening the chest, and cardiopulmonary bypass) and removing a portion of the interventricular septum. Surgical myectomy resection that focuses just on the subaortic septum, to increase the size of the outflow tract to reduce Venturi forces, may be inadequate to abolish systolic anterior motion (SAM) of the anterior leaflet of the mitral valve. With this limited resection, the residual mid-septal bulge still redirects flow posteriorly; SAM persists because flow still gets behind the mitral valve. It is only when the deeper portion of the septal bulge is resected that flow is redirected anteriorly away from the mitral valve, abolishing SAM. With this in mind, a modification of the Morrow myectomy termed extended myectomy, mobilization and partial excision of the papillary muscles has become the excision of choice. In people with particularly large redundant mitral valves, anterior leaflet plication may be added to complete separation of the mitral valve and outflow. Complications of septal myectomy surgery include possible death, arrhythmias, infection, incessant bleeding, septal perforation/defect, and stroke.
Alcohol septal ablation
Alcohol septal ablation, introduced by Ulrich Sigwart in 1994, is a percutaneous technique that involves injection of alcohol into one or more septal branches of the left anterior descending artery. This is a catheter technique with results similar to the surgical septal myectomy procedure but is less invasive, since it does not involve general anaesthesia and opening of the chest wall and pericardium (which are done in a septal myectomy). In a select population with symptoms secondary to a high outflow tract gradient, alcohol septal ablation can reduce the symptoms of HCM. In addition, older individuals and those with other medical problems, for whom surgical myectomy would pose increased procedural risk, would likely benefit from the less-invasive septal ablation procedure.
When performed properly, an alcohol septal ablation induces a controlled heart attack, in which the portion of the interventricular septum that involves the left ventricular outflow tract is infarcted and will contract into a scar. There is debate over which people are best served by surgical myectomy, alcohol septal ablation, or medical therapy.
Since 2013, mitral clips have been implanted via catheter as a new strategy to correct the motion of the mitral valve in people with severe obstructive HCM. The device fastens together the mitral valve leaflets to improve the heart's blood outflow. The mitral clip has not yet established the long-term reliability of septal myectomy or alcohol septal ablation, but HCM specialists are increasingly offering the clip as a less-invasive treatment option.
Implantable pacemaker or defibrillator
The use of a pacemaker has been advocated in a subset of individuals, in order to cause asynchronous contraction of the left ventricle. Since the pacemaker activates the interventricular septum before the left ventricular free wall, the gradient across the left ventricular outflow tract may decrease. This form of treatment has been shown to provide less relief of symptoms and less of a reduction in the left ventricular outflow tract gradient when compared to surgical myectomy. Technological advancements have also led to the development of a dual-chamber pacemaker, which is only turned on when needed (in contrast to a regular pacemaker which provides a constant stimulus). Although the dual-chamber pacemaker has shown to decrease ventricular outflow tract obstruction, experimental trials have found only a few individuals with improved symptoms. Unfortunately, researchers suspect that these reports of improved symptoms are due to a placebo effect.
The procedure includes an incision on the anterolateral area below the clavicle. Two leads are then inserted; one into the right atrium and the other into the right ventricular apex via the subclavian veins. Once in place, they are secured and attached to the generator which will remain inside the fascia, anterior to the pectoral muscle. Complications of this procedure include infection, electrical lead and generator malfunction which will require replacement.
For people with HCM who exhibit one or more of the major risk factors for sudden cardiac death, an implantable cardioverter-defibrillator (ICD) or a combination pacemaker/ICD all-in-one unit may be recommended as an appropriate precaution.
In cases that are unresponsive to all other forms of treatment, cardiac transplantation is one option. It is also the only treatment available for end-stage heart failure. However, transplantation must occur before the onset of symptoms such as pulmonary vessel hypertension, kidney malfunction, and thromboembolism in order for it to be successful. Studies have indicated a seven-year survival rate of 94% in people with HCM after transplantation.
A systematic review from 2002 concluded that: "Overall, HCM confers an annual mortality rate of about 1%... HCM may be associated with important symptoms and premature death but more frequently with no or relatively mild disability and normal life expectancy."
Even though hypertrophic cardiomyopathy (HCM) may be present early in life and is most likely congenital, it is one of the most-uncommon cardiac malformations encountered in pediatric cardiology, largely because the presentation of symptoms is usually absent, incomplete, or delayed into adulthood. Most of the current information pertaining to HCM arises from studies in adult populations, and the implication of these observations for pediatric population is often uncertain. Nonetheless, recent studies in pediatric cardiology have revealed that HCM accounts for 42% of childhood cardiomyopathies, with an annual incidence rate of 0.47/100,000 in children. Further, in asymptomatic cases, sudden death is considered one of the most-feared complications associated with the disease in select pediatric populations. Consequently, the recommended practice is to screen children of affected individuals throughout childhood to detect cardiac abnormalities at an early stage, in the hope of preventing further complications of the disease.
Generally, the diagnosis of HCM in a pediatric population is made during assessment for murmur, congestive heart failure, physical exhaustion, and genetic testing of children of affected individuals. Specifically, echocardiogram (ECHO) has been used as a definitive noninvasive diagnostic tool in nearly all children. ECHO assesses cardiac ventricular size, wall thickness, systolic and diastolic function, and outflow obstruction. Thus, ECHO has been chosen as an ideal means to detect excessive wall thickening of cardiac muscle in HCM.
For children with HCM, treatment strategies aim to reduce disease symptoms and lower the risk of sudden death. Due to the heterogeneity of the disease, treatment is usually modified according to individual's needs. β-blockers improve left ventricular filling and relaxation and thereby improve symptoms. In some children, β–blockers (e.g., propranolol) were shown effective to reduce the risk of sudden death. Further, calcium channel blockers (verapamil) and antiarrhythmic drugs may be used as an adjunct therapy to β-blockers in symptomatic children. Nonetheless, further testing is needed to determine their definitive benefits.
Feline hypertrophic cardiomyopathy (HCM) is the most common heart disease in domestic cats; the disease process and genetics are believed to be similar to the disease in humans. In Maine Coon cats, HCM has been confirmed as an autosomal dominant inherited trait. Numerous cat breeds have HCM as a problem in the breed. The first genetic mutation (in cardiac myosin binding protein C) responsible for feline HCM was discovered in 2005 in Maine Coon cats. A test for this mutation (A31P) is available. About one-third of Maine Coon cats tested for the mutation are either heterozygous or homozygous for the mutation, although many of the cats that are heterozygous have no overt evidence of the disease on an echocardiogram (low penetrance). Some Maine Coon cats with clinical evidence of hypertrophic cardiomyopathy test negative for this mutation, strongly suggesting that another cause exists in the breed. The cardiac myosin binding protein C mutation identified in Maine Coon cats has not been found in any other breed of cat with HCM, but more recently another myosin binding protein C mutation has been identified in Ragdoll cats with HCM. As in humans, feline HCM is not present at birth but develops over time. It has been identified for the first time in cats as young as 6 months of age and at least as old as 7 years of age.
Clinically, cats with hypertrophic cardiomyopathy commonly have a systolic anterior motion of the mitral valve (see graphic). Cats with severe HCM often develop left heart failure (pulmonary edema; pleural effusion) because of severe diastolic dysfunction of the left ventricle. They may also develop a left atrial thrombus that embolizes, most commonly, to the terminal aorta creating acute pain and rear limb paralysis (see below). Sudden death can also occur but appears to be uncommon.
There is no cure for feline HCM. Many but not all cats have a heart murmur. Many cats that have a heart murmur do not have HCM. Frequently the first signs that a cat has HCM are tachypnea/dyspnea due to heart failure or acute pain and paralysis due to systemic thromboembolism. While medication is commonly given to cats with HCM that have no clinical signs, no medication has been shown to be helpful at this stage and it has been shown that an ACE inhibitor is not beneficial until heart failure is present (at which time a diuretic is most beneficial). Diltiazem generally produces no demonstrable benefit. Atenolol is commonly administered when a severe systolic anterior motion of the mitral valve is present.
Feline arterial thromboembolism (FATE) is a relatively common and devastating complication of feline HCM and other feline cardiomyopathies. The thrombus generally forms in the left atrium, most commonly the left auricle. The formation is thought to be primarily due to blood flow stasis. Classically, the thromboembolism lodges at the iliac trifurcation of the aorta, occluding either one or both of the common iliac arteries. Because this split is called the saddle, and is the most frequent location for the thrombus, FATE is commonly known as saddle thrombus. Clinically this presents as a cat with complete loss of function in one or both hind limbs. The hind limbs are cold and the cat is in considerable pain. Emboli may, rarely, lodge in other locations, most commonly the right front limb and the renal arteries.
Clopidogrel (Plavix) is used to try to prevent left atrial thrombus formation in cats with HCM and a large left atrium. The FATCAT study at Purdue University demonstrated that it is superior to aspirin for the prevention of a second thrombus from forming in cats that have already experienced a clot. Thrombolytic agents (e.g., tissue plasminogen activator) have been used with some success to break down an existing aortic thromboembolism, but their cost is high and outcome appears to be no better than giving a cat time (48–72 hours) to break down its own clot. Pain management is extremely important. The prognosis for cats with FATE is often poor as they are likely to have significant HCM already and a recurrent bout of FATE is likely. For this reason, euthanasia is often a valid consideration.
In July 2013, Rigo, a 42-year-old western lowland gorilla, resident in Melbourne Zoo and father of Mzuri, the first gorilla born by artificial insemination, died unexpectedly as a result of HCM. The condition is not uncommon in male gorillas over the age of 30, and in many cases, there is no sign of the disease until the individual's sudden death.
- "Other Names for Cardiomyopathy". NHLBI. June 22, 2016. Retrieved 31 August 2016.
- "What Are the Signs and Symptoms of Cardiomyopathy?". NHLBI. 22 June 2016. Retrieved 10 November 2017.
- "What Is Cardiomyopathy?". NHLBI. 22 June 2016. Retrieved 10 November 2017.
- Barsheshet, Alon; Brenyo, Andrew; Moss, Arthur; Goldenberg, Ilan (July 2011). "Genetics of Sudden Cardiac Death". Current Cardiology Reports. 13 (5): 364–376. doi:10.1007/s11886-011-0209-y. PMID 21789574.
- Ferri, Fred F. (2017). Ferri's Clinical Advisor 2018 E-Book: 5 Books in 1. Elsevier Health Sciences. p. 246. ISBN 9780323529570.
- "What Causes Cardiomyopathy?". NHLBI. 22 June 2016. Retrieved 10 November 2017.
- Gersh BJ, Maron BJ, Bonow RO, et al. (December 2011). "2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary". J. Thorac. Cardiovasc. Surg. 142 (6): 1303–38. doi:10.1016/j.jtcvs.2011.10.019. PMID 22093712.
- Maron, BJ; Ommen, SR; Semsarian, C; Spirito, P; Olivotto, I; Maron, MS (8 July 2014). "Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine". Journal of the American College of Cardiology. 64 (1): 83–99. doi:10.1016/j.jacc.2014.05.003. PMID 24998133.
- "Types of Cardiomyopathy". NHLBI. 22 June 2016. Retrieved 10 November 2017.
- Teare D (1958). "Asymmetrical hypertrophy of the heart in young adults". British Heart Journal. 20 (1): 1–8. doi:10.1136/hrt.20.1.1. PMC 492780. PMID 13499764.
- McKenna WJ, Sen-Chowdhry S (2008). "From Teare to the Present Day: A Fifty Year Odyssey in Hypertrophic Cardiomyopathy, a Paradigm for the Logic of the Discovery Process". Revista Española de Cardiología. 61 (12): 1239–1244. doi:10.1016/S1885-5857(09)60050-5. PMID 19080961.
- Maron, Barry J. (2002-03-13). "Hypertrophic Cardiomyopathy". JAMA. 287 (10): 1308–20. doi:10.1001/jama.287.10.1308. ISSN 0098-7484. PMID 11886323.
- Fifer, Michael A.; Vlahakes, Gus J. (2008-01-22). "Management of Symptoms in Hypertrophic Cardiomyopathy". Circulation. 117 (3): 429–439. doi:10.1161/CIRCULATIONAHA.107.694158. ISSN 0009-7322. PMID 18212300.
- Bonow R, Braunwald E, Zipes DP, Libby P (2005). "The Cardiomyopathies". Braunwald's heart disease: a textbook of cardiovascular medicine (7th ed.). Philadelphia: WB Saunders. ISBN 978-1-4160-0014-3.
- Wigle, E. D.; Rakowski, H.; Kimball, B. P.; Williams, W. G. (1995-10-01). "Hypertrophic cardiomyopathy. Clinical spectrum and treatment". Circulation. 92 (7): 1680–1692. doi:10.1161/01.cir.92.7.1680. ISSN 0009-7322. PMID 7671349.
- Maron BJ, McKenna WJ, Danielson GK, et al. (Nov 2003). "American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy". J Am Coll Cardiol. 42 (9): 1687–1713. doi:10.1016/S0735-1097(03)00941-0. PMID 14607462.
- Murphy, Joseph G.; Lloyd, Margaret A. (2007). Mayo Clinic Cardiology Concise Textbook and Mayo Clinic Cardiology Board Review Questions & Answers: (TEXT AND Q&A SET). CRC Press. p. 1159. ISBN 9781439825457.
- Cirino, Allison L; Ho, Carolyn (2014). "Hypertrophic Cardiomyopathy Overview". In Pagon, Roberta A; Adam, Margaret P; et al. (eds.). GeneReviews. University of Washington, Seattle.
- Doolan G, Nguyen L, Chung J, Ingles J, Semsarian C (Aug 2004). "Progression of left ventricular hypertrophy and the angiotensin-converting enzyme gene polymorphism in hypertrophic cardiomyopathy". Int J Cardiol. 96 (2): 157–63. doi:10.1016/j.ijcard.2004.05.003. PMID 15314809.
- Marian AJ, Yu QT, Workman R, Greve G, Roberts R (Oct 1993). "Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death". Lancet. 342 (8879): 1085–6. doi:10.1016/0140-6736(93)92064-Z. PMID 8105312.
- Pasquale F, Syrris P, Kaski JP, Mogensen J, McKenna W, Elliott P (Feb 2012). "Long-term outcomes in hypertrophic cardiomyopathy caused by mutations in the cardiac troponin T gene". Circ Cardiovasc Genet. 5 (1): 10–17. doi:10.1161/CIRCGENETICS.111.959973. PMID 22144547.
- Sedaghat-Hamedani F, Kayvanpour E, Tugrul OF, Lai A, Amr A, Haas J, Proctor T, Ehlermann P, Jensen K, Katus HA, Meder B (2018). "Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals". Clinical Research in Cardiology. 107 (1): 30–41. doi:10.1007/s00392-017-1155-5. PMID 28840316.
- Gollob, Michael H, et al. (2011). "Recommendations for the Use of Genetic Testing in the Clinical Evaluation of Inherited Cardiac Arrhythmias Associated with Sudden Cardiac Death: Canadian Cardiovascular Society/Canadian Heart Rhythm Society Joint Position Paper". Canadian Journal of Cardiology. 27 (2): 232–245. doi:10.1016/j.cjca.2010.12.078. PMID 21459272.
- Sievert, Horst; Qureshi, Shakeel A.; Wilson, Neil; Hijazi, Ziyad M. (2015). Interventions in Structural, Valvular and Congenital Heart Disease, Second Edition. CRC Press. p. 46. ISBN 9781482215649.
- Rivera-Diaz, Jorge; Moosvi, Ali R. (July 1996). "Apical hypertrophic cardiomyopathy". South. Med. J. 89 (7): 711–713. doi:10.1097/00007611-199607000-00012. PMID 8685759.
- Maron BJ (March 2002). "Hypertrophic cardiomyopathy: a systematic review". JAMA. 287 (10): 1308–1320. doi:10.1001/jama.287.10.1308. ISSN 0098-7484. PMID 11886323.
- Behr, Elijah; McKenna, William (2002). "Hypertrophic Cardiomyopathy". Current Treatment Options in Cardiovascular Medicine. 4 (6): 443–453. doi:10.1007/s11936-002-0039-8. PMID 12408787.
- Corrado D, Basso C, Pavei A, Michieli P, Schiavon M, Thiene G (2006). "Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program". JAMA. 296 (13): 1593–601. doi:10.1001/jama.296.13.1593. PMID 17018804.
- Critoph, Christopher; Elliott, Perry (2010). "Hypertrophic Cardiomyopathy". Cardiac Electrophysiology Clinics. 2 (4): 587–598. doi:10.1016/j.ccep.2010.09.010. PMID 28770721.
- Germans, Tjeerd; Wilde, Arthur A.M.; Dijkmans, Pieter A.; Chai, Wenxia; Kamp, Otto; Pinto, Yigal M.; van Rossum, Albert C. (2006). "Structural Abnormalities of the Inferoseptal Left Ventricular Wall Detected by Cardiac Magnetic Resonance Imaging in Carriers of Hypertrophic Cardiomyopathy Mutations". Journal of the American College of Cardiology. 48 (12): 2518–2523. doi:10.1016/j.jacc.2006.08.036. PMID 17174192.
- Coats, Caroline; Elliott, Perry (2008). "Current management of hypertrophic cardiomyopathy". Current Treatment Options in Cardiovascular Medicine. 10 (6): 496–504. doi:10.1007/s11936-008-0042-9. PMID 19026180.
- Maron BJ (March 2010). "National electrocardiography screening for competitive athletes: Feasible in the United States?". Ann. Intern. Med. 152 (5): 324–6. CiteSeerX 10.1.1.668.3787. doi:10.7326/0003-4819-152-5-201003020-00012. PMID 20194239.
- Maron, BJ.; Doerer, JJ.; Haas, TS.; Tierney, DM.; Mueller, FO. (Mar 2009). "Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006". Circulation. 119 (8): 1085–92. doi:10.1161/CIRCULATIONAHA.108.804617. PMID 19221222.
- Maron, BJ.; Gohman, TE.; Aeppli, D. (Dec 1998). "Prevalence of sudden cardiac death during competitive sports activities in Minnesota high school athletes". J Am Coll Cardiol. 32 (7): 1881–4. doi:10.1016/S0735-1097(98)00491-4. PMID 9857867.
- Hershberger, Ray; Lindenfeld, Joann; Mestroni, Luisa; Seidman, Christine E.; Taylor, Matthew R.G.; Towbin, Jeffrey A.; Heart Failure Society of America (2009). "Genetic Evaluation of Cardiomyopathy: A Heart Failure Society of America Practice Guideline". Journal of Cardiac Failure. 15 (2): 83–97. doi:10.1016/j.cardfail.2009.01.006. PMID 19254666.
- Espinoza, Javier (31 January 2016). "Sir David Frost's son 'unaware of fatal heart condition'". Daily Telegraph. Retrieved 1 February 2016.
- Sherrid MV, Chaudhry FA, Swistel DG (Feb 2003). "Obstructive hypertrophic cardiomyopathy: echocardiography, pathophysiology, and the continuing evolution of surgery for obstruction". Ann. Thorac. Surg. 75 (2): 620–32. doi:10.1016/S0003-4975(02)04546-0. PMID 12607696.
- Messmer BJ (Aug 1994). "Extended myectomy for hypertrophic obstructive cardiomyopathy". Ann. Thorac. Surg. 58 (2): 575–7. doi:10.1016/0003-4975(94)92268-3. PMID 8067875.
- Schoendube FA, Klues HG, Reith S, Flachskampf FA, Hanrath P, Messmer BJ (Nov 1995). "Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus". Circulation. 92 (9 Suppl): II122–7. doi:10.1161/01.CIR.92.9.122. PMID 7586394.
- Balaram SK, Sherrid MV, Derose JJ, Hillel Z, Winson G, Swistel DG (Jul 2005). "Beyond extended myectomy for hypertrophic cardiomyopathy: the resection-plication-release (RPR) repair". Ann. Thorac. Surg. 80 (1): 217–23. doi:10.1016/j.athoracsur.2005.01.064. PMID 15975370.
- Sigwart, Ulrich (22 July 1995). "Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy". Lancet. 346 (8969): 211–214. doi:10.1016/S0140-6736(95)91267-3. PMID 7616800.
- Heldman AW, Wu KC, Abraham TP, Cameron DE (Jan 2007). "Myectomy or alcohol ablation surgery and percutaneous intervention go another round". J Am Coll Cardiol. 49 (3): 358–60. doi:10.1016/j.jacc.2006.10.029. PMID 17239718.
- Dimitrow PP, Rajtar-Salwa R (May 2016). "Obstructive Form of Hypertrophic Cardiomyopathy – Left Ventricular Outflow Tract Gradient: Novel Methods of Provocation, Monitoring of Biomarkers, and Recent Advances in the Treatment". BioMed Research International. 2016 (1575130): 1575130. doi:10.1155/2016/1575130. PMC 4877458. PMID 27247935.
- Sorajja P, Pedersen WA, Bae R, Lesser JR, Jay D, Lin D, Harris K, Maron BJ (June 2016). "First Experience With Percutaneous Mitral Valve Plication as Primary Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy" (PDF). J Am Coll Cardiol. 67 (24): 2811–2818. doi:10.1016/j.jacc.2016.03.587. PMID 27311518.
- Ommen SR, Nishimura RA, Squires RW, Schaff HV, Danielson GK, Tajik AJ (Jul 1999). "Comparison of dual-chamber pacing versus septal myectomy for the treatment of patients with hypertrophic obstructive cardiomyopathy: a comparison of objective hemodynamic and exercise end points". J Am Coll Cardiol. 34 (1): 191–6. doi:10.1016/S0735-1097(99)00173-4. PMID 10400010.
- Maron BJ, Spirito P, Shen W, et al. (2007). "Implantable Cardioverter-Defibrillators and Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy". JAMA. 298 (4): 405–412. doi:10.1001/jama.298.4.405. PMID 17652294.
- "ICDs and Pacemakers". Hypertrophic Cardiomyopathy Association. Retrieved November 14, 2016.
- Colan, Steven (October 2010). "Hypertrophic Cardiomyopathy in Childhood". Heart Fail Clin. 6 (4): 433–444. doi:10.1016/j.hfc.2010.05.004. PMC 2946944. PMID 20869644.
- Lipshultz, SE; Sleeper LA; Towbin JA (2003). "The incident of pediatric cardiomyopathy in two regions of the United States". N. Engl. J. Med. 348 (17): 1647–55. doi:10.1056/NEJMoa021715. PMID 12711739.
- Maskatia, Shiraz (2012). "Hypertrophic cardiomyopathy: infants, children and adolescents". Congenit Heart Dis. 7 (1): 84–92. doi:10.1111/j.1747-0803.2011.00613.x. PMID 22222117.
- "Hypertrophic Cardiomyopathy (HCM) in Cats". Cornell University Hospital for Animals. Retrieved 24 February 2017.
- Kittleson M, Meurs K, Munro M, Kittleson J, Liu S, Pion P, Towbin J (1999). "Familial hypertrophic cardiomyopathy in Maine coon cats: an animal model of human disease". Circulation. 99 (24): 3172–80. doi:10.1161/01.CIR.99.24.3172. PMID 10377082.
- Kittleson, Mark; Gompf, Rebecca; Little, Susan. "Feline Hypertrophic Cardiomyopathy: Advice for Breeders". Cat Fancier's Association. Archived from the original on May 13, 2008.
- Meurs K, Sanchez X, David R, Bowles N, Towbin J, Reiser P, Kittleson J, Munro M, Dryburgh K, Macdonald K, Kittleson M (2005). "A cardiac myosin binding protein C mutation in the Maine Coon cat with familial hypertrophic cardiomyopathy". Hum Mol Genet. 14 (23): 3587–93. doi:10.1093/hmg/ddi386. PMID 16236761.
- "Genetics: Maine Coon Cat Hypertrophic Cardiomyopathy". North Carolina State University, College of Veterinary Medicine. Retrieved December 29, 2016.
- Meurs KM, Norgard MM, Ederer MM, Hendrix KP, Kittleson MD (2007). "A substitution mutation in the myosin binding protein C gene in Ragdoll hypertrophic cardiomyopathy". Genomics. 90 (2): 261–264. doi:10.1016/j.ygeno.2007.04.007. PMID 17521870.
- "Genetics: Ragdoll Cat Hypertrophic Cardiomyopathy". North Carolina State University, College of Veterinary Medicine. Retrieved December 29, 2016.
- MacDonald K, Kittleson M, Larson R, Kass P, Klose T, Wisner E (2006). "The effect of ramipril on left ventricular mass, myocardial fibrosis, diastolic function, an plasma neurohormones in Maine Coon cats with familial hypertrophic cardiomyopathy without heart failure". J Vet Intern Med. 20 (5): 1093–1105. doi:10.1111/j.1939-1676.2006.tb00707.x. PMID 17063701.
- "The Fragile Fate of FATEs: The Management and Prognosis of Feline Aortic Thromboembolism". Massachusetts Society for the Prevention of Cruelty to Animals-Angell. Retrieved October 8, 2016.
- Borgeat K, Wright J, Garrod O, Payne JR, Fuentes VL (2014). "Arterial thromboembolism in 250 cats in general practice: 2004-2012". Journal of Veterinary Internal Medicine. 28 (1): 102–108. doi:10.1111/jvim.12249. PMC 4895537. PMID 24237457.
- Smith, Bridie (2013-07-26). "Silverback gorilla Rigo died of heart failure at Melbourne Zoo". The Age. Retrieved 2013-07-26.
- Hypertrophic cardiomyopathy at Curlie
- GeneReviews/NIH/NCBI/UW entry on Familial Hypertrophic Cardiomyopathy Overview
- National Heart, Blood, and Lung Institute Cardiomyopathy Page
This article is a direct transclusion of the Wikipedia article and therefore may not meet the same editing standards as LIMSwiki.